Holen Sie sich die Stockscreener-App
2.695
4.05%
0.105
Handel nachbörslich:
2.71
0.015
+0.56%
Schlusskurs vom Vortag:
$2.59
Offen:
$2.64
24-Stunden-Volumen:
117.25K
Relative Volume:
1.11
Marktkapitalisierung:
$17.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.46M
KGV:
-0.1925
EPS:
-14
Netto-Cashflow:
$-24.56M
1W Leistung:
-11.49%
1M Leistung:
-0.92%
6M Leistung:
+44.12%
1J Leistung:
-84.19%
1-Tages-Spanne:
$2.52
$2.71
1-Wochen-Bereich:
$2.52
$3.05
52-Wochen-Spanne:
$1.20
$17.75
Evaxion A S Adr Stock (EVAX) Company Profile
Vergleichen Sie EVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
2.695 | 17.53M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-02 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | Eingeleitet | H.C. Wainwright | Buy |
Evaxion A S Adr Aktie (EVAX) Neueste Nachrichten
Evaxion Biotech A/S Adr Earnings Call: Strategic Growth Amid Challenges - TipRanks
Evaxion Biotech Reports Q2 2025 Financial Results - MSN
Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
XTX Topco Ltd Makes New Investment in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) - Defense World
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
European Equities See Growth In US Trade - Finimize
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
Evaxion secures Nasdaq listing with equity boost - Investing.com
H.C. Wainwright maintains Evaxion stock Buy rating, $14 target - Investing.com
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
Evaxion Biotech stock hits 52-week low at $3.06 amid sharp decline - Investing.com
Evaxion Biotech Completes 1:5 Reverse ADS Split: What Investors Need to Know - Stock Titan
Evaxion Biotech stock hits 52-week low at $0.81 amid market challenges - Investing.com
Evaxion Biotech A/S Announces Change in American Depositary Shares Ratio to Enhance Liquidity - Nasdaq
Evaxion Biotech stock hits 52-week low at $0.84 amid market challenges - Investing.com
Evaxion Biotech stock hits 52-week low at $0.92 - Investing.com
Earnings call: Evaxion Biotech reports Q2 results, optimistic on EVX-01 - Investing.com
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data - Nasdaq
European Equities Traded as American Depositary Receipts Down Fall - TradingView
Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' Now - Nasdaq
Finanzdaten der Evaxion A S Adr-Aktie (EVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):